Better Detection of Peripheral Arterial Disease with Toe-Brachial Index Compared to Ankle-Brachial Index among Taiwanese Patients with Diabetic Kidney Disease
1
School of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
2
Department of Nursing, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
3
Statistical Analysis Laboratory, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
4
Department of Business Management, National Sun Yat-Sen University, Kaohsiung 803, Taiwan
5
Administration Management Center, Kaohsiung Siaogang Municipal Hospital, Kaohsiung 812, Taiwan
6
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
7
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
8
Department of Internal Medicine, Kaohsiung Medical University Gangshan Hospital, Kaohsiung 820, Taiwan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(23), 7393; https://doi.org/10.3390/jcm12237393
Submission received: 17 October 2023
/
Revised: 21 November 2023
/
Accepted: 25 November 2023
/
Published: 29 November 2023
(This article belongs to the Special Issue Chronic Complications of Diabetes: Prevalence, Prevention and Management)
Abstract
:Background: Ankle-brachial index (ABI) is a simple method for diagnosing peripheral artery disease (PAD) but has limited reliability in patients with diabetes mellitus (DM) because of medial artery calcification. Our study aims to investigate whether the toe brachial index (TBI) or the cardio-ankle vascular index (CAVI) has a better detection over the ABI for diagnosing PAD in diabetic kidney disease (DKD). Materials and Methods: A cohort of 368 patients (mean age 68.59 ± 13.14 years, 190 males and 178 females) with type 2 DM underwent ABI, TBI, and CAVI measurements at our outpatient clinic. Results: Of all enrolled patients, the TBI is significant in evaluating PAD, especially in patients whose chronic kidney disease (CKD) stage 3a with adjusted odds ratio (AOR) = 6.50, 95% confidence interval (CI) 1.63–25.97, p = 0.0080, stage 3b AOR = 7.47, 95% CI 1.52–36.81, p = 0.0135, and stage 4–5 AOR = 20.13, 95% CI 1.34–94.24, p = 0.0116. CAVI is also significant in CKD stage 1 with AOR = 0.16, 95% CI 0.03–0.77, p = 0.0223, stage 2 with AOR = 0.18, 95% CI 0.04–0.74, p = 0.0180, and stage 3a AOR = 0.31, 95% CI 0.10–0.93, p = 0.0375. Conclusion: TBI has a better yield of detection of PAD compared to ABI among Taiwanese patients with DKD. CAVI may play a role in the early stage of DKD.
1. Introduction
In patients with type 2 diabetes, cardiovascular disease (CVD) is the most common cause of mortality and morbidity [1]. Diabetes mellitus increases microvascular complications, which include retinopathy, nephropathy, and neuropathy. Also, it may lead to macrovascular complications. Furthermore, patients with CKD are related to elevated cardiovascular risk manifesting as CVD [2]. Based on a previous systemic review that assessed community-based studies for global prevalence and risk factors of PAD, DM ranked as the second major risk [3]. According to the National Health and Nutrition Examination Survey, DM and smoking were also the most significant risk factors for PAD [4].
The ABI is a simple and noninvasive method to assess PAD [5], and an ABI value < 0.9 is sensitive for the diagnosis of PAD. However, the application of this index to diabetic patients is considered questionable because of medial artery calcification, which is a nonobstructive calcification of the tunica media that occurs commonly in the arteries of older adults and diabetic kidney disease patients; these factors could mistakenly elevate the ABI value [6,7]. Therefore, considering the medial artery calcification, the TBI is an alternative measure to the ABI to evaluate for PAD [8], TBI may be more specific to diagnosing PAD and identifying patients at risk for CVD. Arterial stiffness is the lack of viscoelastic properties of the arterial wall due to many reasons, including DM, vascular calcification, and hypertension [9]. CAVI is a newly developed method used to assess arterial stiffness such as common iliac, femoral, and tibial artery levels. Arterial stiffness is not affected by blood pressure; therefore, high CAVI can also be a predictor of CVD in CKD patients. However, using CAVI as a tool to assess and evaluate PAD in DKD patients is still under investigation. Knowing that PAD, a disease of the major arteries caused by atherosclerosis, is a vascular complication of DM [10], our study aims to determine which of the three measures, ABI, TBI, and CAVI, has the highest detection of PAD among patients with diabetic kidney disease.
2. Materials and Methods
2.1. Study Patients
Patients with type 2 DM who visited the Endocrinology and Metabolism outpatient department of the Southern Taiwan Medical Center between February 2022 and May 2022 were included in the study. We excluded patients with type 1 DM (defined as a presentation with diabetic ketoacidosis, acute hyperglycemia symptoms with heavy ketonuria (≥3), or the continuous requirement of insulin in the year succeeding diagnosis). Finally, 368 patients (mean age 68.59 ± 13.14 years, 190 males and 178 females) were included in this study.
2.2. Ethics Statement
The study protocol was approved by the institutional review board of the Kaohsiung Medical University Hospital (KMUHIRB-E(I)-20210313). Informed consent was obtained in written form from patients and all clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The patients gave consent for the publication of the clinical details.
2.3. Assessment of ABI, TBI, and CAVI
The values of ABI, TBI, and CAVI were determined from the measurements by VS-2000 (Fukuda Denshi Corporation., Tokyo, Japan), which automatically and simultaneously measured blood pressures and pulse volumes in both arms and ankles or toe using an oscillometric method [11,12,13]. ABI and TBI were measured after allowing the patient to rest in a supine position for at least 5 min. The ABI and TBI were calculated by the ratio of the ankle or toe systolic blood pressure divided by the arm systolic blood pressure. The ABI and TBI measurements were conducted once in each patient. PAD can be diagnosed noninvasively by segmental blood pressure measurement and calculating an ABI or TBI. The diagnosis of PAD was defined as ABI < 0.9 or ≥1.3 in either leg or TBI below 0.65. The validation of this automatic device and its reproducibility had been previously published [12].
CAVI integrates information about the elasticity of blood vessels and represents a novel parameter of vascular stiffness that does not depend on BP [14]. The mathematical expression to calculate CAVI values is described elsewhere [14,15] and is mainly based on substituting the stiffness parameters β and PWV in the following equation: β = 2ρ × 1/(SBP − DBP) × ln (SBP/DBP) × PWV2, where ρ is the blood density and PWV is the heart–ankle PWV (haPWV) measured between the origin of the aorta and the tibial artery at the ankle. The mean coefficient of variation of CAVI is <5%, which is small enough for clinical use. The CAVI values, according to age and gender, are classified as normal (CAVI < 8), borderline (8 ≤ CAVI < 9), and abnormal (CAVI ≥ 9) [15].
The above measurements of ABI, TBI, and CAVI were all performed by our single technician to ensure the standardization of the readings.
2.4. Collection of Demographic, Medical, and Laboratory Data
Demographic and medical data including age, gender, and co-morbid conditions were obtained from medical records and interviews with patients. The cardiovascular diseases included histories of old myocardial infarction and stroke, ischemic heart disease, atherosclerotic cardiovascular disease, and angina. The body mass index (BMI) was calculated as the ratio of weight in kilograms divided by the square of height in meters. Laboratory data were measured from fasting blood samples using an autoanalyzer (Roche Diagnostics GmbH, D-68298 Mannheim COBAS Integra 400, Basel, Switzerland). Serum creatinine was measured by the compensated Jaffé (kinetic alkaline picrate) method in a Roche/Integra 400 Analyzer (Roche Diagnostics, Mannheim, Germany) using a calibrator traceable to isotope-dilution mass spectrometry [16]. The value of eGFR was calculated using the 4-variable equation in the Modification of Diet in Renal Disease (MDRD) study, and CKD staging was as follows: stage 1 for estimated glomerular filtration rate (eGFR) of >90 mL/min/1.73 m2, stage 2 for eGFR of 60–89 mL/min/1.73 m2, stage 3a for eGFR of 45–59 mL/min/1.73 m2, stage 3b for eGFR of 30–44 mL/min/1.73 m2, stage 4 for eGFR of 15–29 mL/min/1.73 m2, and stage 5 for eGFR of <15 mL/min/1.73 m2 [17]. Urine albumin and creatinine were measured on a spot urine sample by an autoanalyzer (COBAS Integra 400 plus; Roche Diagnostics, North America). The urine albumin–creatinine ratio (UACR) was categorized into three groups: normoalbuminuria with urine ACR 0–29 mg/gm, microalbuminuria with urine ACR 30–299 mg/gm, and macroalbuminuria with urine ACR > 300 mg/gm. Blood samples were obtained within 1 month of ABI measurement. In addition, information regarding patient medications, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), β-blockers, calcium channel blockers, diuretics, HMG-CoA reductase inhibitors (statins) and fibrates, oral antidiabetic agents like sulfonylureas, metformin, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitor (DPP4-I), sodium-glucose co-transporter 2 inhibitors (SGLT2-I), and insulin, during the study period was obtained from medical records.
2.5. Statistical Analysis
Statistical analysis was performed using SPSS 19.0 for Windows (SPSS Inc. Chicago, IL, USA). The sample size was calculated using the G-power of binary logistic regression. The G-power of ABI is 66.54%, TBI is 99.99%, and CAVI is 98.92%. Data are expressed as percentages, mean ± standard deviation, or median (25th–75th percentile) for age, DM duration years, total cholesterol, triglyceride, low and high-density lipoproteins, fasting glucose, HbA1c, creatinine, BMI, and systolic and diastolic blood pressures. The differences between groups were checked using a Chi-square test for categorical variables and an independent t-test for continuous variables. Multiple forward logistic regression analysis after adjustment of age, sex, DM duration coronary artery disease, systolic and diastolic blood pressures, BMI, hemoglobin A1c, fasting glucose, triglyceride, total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, eGFR, microalbuminuria and CKD stages, anti-hypertensive and anti-diabetic medications, and lipid-lowering medication use were used to identify the factors associated with an abnormal ABI, TBI, and CAVI. A difference was considered significant if the p-value was less than 0.05.
3. Results
A total of 368 patients with type 2 DM were included (mean age 68.59 ± 13.14 years; 190 males and 178 females), with some having different stages of chronic kidney disease (CKD).
Comparisons of baseline characteristics between the patients with (n = 336) and without (n = 32) a normal ABI are shown in Table 1A.
CKD is categorized into stages 1 to 5. The prevalence of a normal ABI (ABI > 0.9) is significantly higher than that of an abnormal ABI (ABI < 0.9), with a p-value of 0.0067. CKD stages 1, 2, and 3a had a higher prevalence in normal than abnormal ABI, (N = 36 (10.7%) versus N = 3 (9.4%), N = 56 (16.7%) versus N = 4 (12.5%), N = 87 (25.9%) versus N = 5 patients (15.6%), p-value = 0.0067). However, stages 3b and 4 + 5 had a higher prevalence of abnormal than normal ABI (N = 51 (15.2%) versus N = 9 patients (28.1%) and N = 27 patients (8.0%) versus N = 8 patients (25%), p-value = 0.067), respectively. Urine ACR < 30 mg/g and 30–299 mg/g had a higher prevalence in normal than in abnormal ABI (N = 149 (44.3%) versus N = 10 (31.3%) and N = 127 (37.8%) versus N = 10 (31.3%), p-value 0.0396). However, urine ACR > 300 mg/g had a higher prevalence in abnormal than in abnormal ABI (N = 60 (17.9%) versus N = 12 (37.5%), p-value = 0.0396). Patients with abnormal ABI had a higher systolic blood pressure (SBP) of 137.20 ± 16.92 mmHg than patients with normal ABI with an SBP of 131.50 ± 15.28 mmHg, with a p-value of 0.0487. Patients with abnormal ABI, N = 14 (43.8%), had a higher prevalence of cardiovascular disease than patients with normal ABI, N = 74 (22.0%), with a p-value of 0.0059. Metformin users had a higher prevalence in normal ABI, N = 241 (71.7%), than in abnormal ABI, N = 16 (50.0%), with a p-value of 0.0105.
Comparisons of baseline characteristics between the patients with (N = 290) and without (N = 78) a normal TBI are shown in Table 1B.
CKD was categorized into stages 1 to 5. CKD stage 3a, 3b, and 4 + 5 had a higher prevalence in abnormal TBI (TBI < 0.65) than normal TBI (TBI > 0.65) with N = 67 (23.1%) versus N = 25 patients (32.1%), N = 44 (15.2%) versus N = 16 patients (20.5%), and N = 22 (7.6%) versus N = 13 patients (16.7%), respectively, with a p-value of 0.0039. While CKD stage 1 and 2 had a higher prevalence in normal than abnormal TBI (N = 33 (11.4%) versus N = 6 (7.7%) and N = 49 (16.9%) versus N = 11 (14.1%), p-value = 0.0039), respectively. Patients with abnormal TBI had a higher prevalence of cardiovascular disease than patients with normal TBI (N = 31 (39.7%) versus N = 57 (19.7%), p-value = 0.0002). Meglitinide users had a higher prevalence in abnormal TBI than normal TBI (N = 8 (10.3%) versus N = 7 (2.4%), p-value = 0.0019). However, diuretics users had a higher prevalence in normal than in abnormal TBI (N = 22 (7.6%) versus N = 18 patients (23.1%), p-value = 0.0001).
Comparisons of baseline characteristics between the patients with (n = 200) and without (n = 168) a normal CAVI are shown in Table 1C. Patients with abnormal CAVI were older and had a longer DM duration than patients with normal CAVI 71.91 ± 8.64 versus 63.18 ± 11.16, with a p-value of 0.0001, and 17.77 ± 9.31 versus 14.13 ± 9.25, with a p-value of 0.0003, respectively. Patients with normal CAVI (28.06 ± 5.70) had a higher body mass index (BMI) than patients with abnormal CAVI (25.69 ± 5.20) with a p-value of <0.0001. Patients who used meglitinides and alpha-glucosidase inhibitors had a higher prevalence of abnormal CAVI (N = 12 (7.1%) versus N = 3 (1.5%), p-value = 0.0064, and N = 20 (11.9%) versus N = 11 (5.5%), p-value = 0.0276, respectively). Alpha-blocker users had a higher prevalence in normal CAVI than in abnormal CAVI (N = 16 (8.0%) versus N = 5 patients (3.0%), with a p-value of 0.0374]).
Table 2 shows the determinants of ABI, TBI, and CAVI in the study patients as determined in multivariable logistic regression analysis. CKD stages 3a, 3b, and 4 + 5 were strongly associated with TBI, with an adjusted odds ratio (AOR) of 6.5, 95% confidence interval (CI): 1.63–25.97, p = 0.0080; AOR 7.47, 95% CI: 1.52–36.81, p = 0.0135; and AOR 20.13, 95% CI: 1.96–206.92, p= 0.0116, respectively. The AOR of TBI shows a value consistently above 1.0 beginning at CKD 3a, implying that this measure is associated with the true CKD stages. Interestingly, CKD stages 1, 2, and 3a were strongly associated with CAVI (AOR 0.16, 95% CI: 0.03–0.77, p = 0.0223; AOR 0.18, 95% CI: 0.04–0.74, p = 0.0180; and AOR 0.31, 95% CI: 0.10–0.93, p = 0.0375, respectively). Older age and longer DM duration were strongly associated with the CAVI level (AOR 1.11, 95% CI: 1.00–1.02, p < 0.0001 and AOR 1.05, 95% CI: 1.01–1.09, p = 0.0282, respectively).
Increased triglycerides and low-density lipoprotein levels were associated with CAVI (AOR 1.01, 95% CI: 1.07–1.16, p = 0.03120 and AOR 1.06, 95% CI: 1.00–1.12, p = 0.0388, respectively). Lower BMI was strongly associated with CAVI (AOR 0.92, 95% CI: 0.85–0.99, p = 0.0223). Higher SBP was strongly associated with ABI (AOR 1.12, 95% CI: 1.03–1.21, p = 0.0090). CVD was associated with both TBI and ABI (AOR 4.0, 95% CI: 1.76–9.11, p = 0.0010 and AOR 7.19, 95% CI: 1.75–29.59, p = 0.0063, respectively). Meglitinide users were associated with both TBI and CAVI (AOR 6.13, 95% CI: 1.05–35.87, p = 0.0444 and AOR 47.27, 95% CI: 2.63–848.93, p = 0.0089, respectively). DPP4 inhibitor users were associated with ABI (AOR 0.10, 95% CI: 0.01–0.67, p = 0.0177). Diuretic users were strongly associated with TBI (AOR 4.19, 95% CI: 1.36–12.90, p = 0.0125). Alpha-blocker was associated with CAVI (AOR 0.13, 95% CI: 0.03–0.60, p = 0.0088).
In summary, our results show that the TBI is significant in evaluating PAD, especially in patients with chronic kidney disease (CKD) stage 3a with adjusted odds ratio (AOR) = 6.50, 95% confidence interval (CI) 1.63–25.97, p= 0.0080, stage 3b AOR = 7.47 95% CI 1.52–36.81, p = 0.0135, and stage 4–5 AOR = 20.13, 95% CI 1.34–94.24, p = 0.0116. CAVI is also significant in CKD stage 1 with AOR = 0.16, 95% CI 0.03–0.77, p = 0.0223, stage 2 with AOR = 0.18, 95% CI 0.04–0.74, p = 0.0180, and stage 3a AOR = 0.31, 95% CI 0.10–0.93, p = 0.0375. Therefore, TBI has a better yield of detection of PAD compared to ABI with DKD.
4. Discussion
In our study, the first important finding is that TBI was strongly associated with CKD stages 3 to 5. Considering the medial artery calcification of the type 2 diabetes population with chronic kidney disease, the TBI is an alternative measure to the ABI to evaluate for PAD [8]. Another important finding of our study is that CAVI was associated with early stages of CKD, stages 1, 2, and 3a, in type 2 diabetes mellitus, which is a good tool to evaluate for arterial stiffness that can assess vascular wall stiffness in the aorta, femoral artery, and tibial artery [14,18].
With respect to PAD, several studies have demonstrated that patients with CKD have a high risk of developing PAD [19]. In addition, results from the United States (US) National Health and Nutrition Examination Survey (NHANES) have reported that the prevalence of PAD in patients with diabetes was higher than in those without diabetes, furthermore, the risk of PAD increased by 2.5 times in patients with eGFR < 60 as compared to eGFR ≥ 60 mL/min/1.73m2, especially with higher ratios in CKD stage 3 to 5 patients. [4]. In an observational study enrolling more than 400.000 patients who were referred to the Manitoba Centre for Health Policy in Manitoba Canada, it was found that PAD is more common in patients with eGFR < 60 mL/min/1.73m2 compared with those with eGFR ≥ 60 mL/min/1.73m2 and frequently leads to lower-limb complications [20]. In 2012, the Kidney Disease Improving Global Outcome (KDIGO) guidelines recommended that adults with non-dialysis CKD be regularly examined for signs of PAD and be considered as candidates for the prescription of evidence-based therapies (Grade 1B) [21]. This meant the new study should assess the burden of PAD in pre-dialysis CKD patients. In hospital-based studies, the prevalence of PAD is 2–3 times higher in patients with versus without T2DM [22]. Various methods, including ABI, TBI, and arterial Doppler, are available to diagnose PAD.
In America, using a TBI cut-off of 0.7, a study has detected PAD (angiographically proven) in dialysis patients characterized by an ABI > 0.9 [23]. In addition, one study in Europe evaluated the predictive impact of the TBI test in people with CKD and ESRD to show that PAD confirmed by a low TBI value was associated with increased all-cause mortality [24]. Furthermore, previous reports have demonstrated that varying degrees of medial arterial calcification are common in diabetic kidney disease patients, so TBI is recommended for diabetic patients and patients with CKD because medial arterial calcification is less common in the toe than in the ankle. For patients with CVD, because of medial arterial calcification in diabetic kidney disease patients, these factors could falsely elevate the ABI value [6,7]; therefore, TBI was alternatively the better tool to evaluate PAD in these patients.
Previous studies also indicated that an increase in the CAVI is closely associated with a decreased eGFR or increased albuminuria [25]. The present study found that patients with macroalbuminuria were associated with abnormal CAVI, whose UACR was over 300 mg/g, so this could be useful for diagnosing patients with diabetic kidney diseases.
The presence of metabolic syndrome has been related to high CAVI as a factor of arterial stiffness [26]. The risk factors of metabolic syndrome include central obesity, elevated blood pressure, high triglycerides, low high-density lipoprotein (HDL), and high fasting glucose [27]. In our study, SBP was associated with ABI. Previous studies have shown that the assessment of 4-limb SBP heterogeneity is useful in the identification of a high-risk group of PAD and/or increased left ventricular mass index (LVMI), irrespective of the presence of overt PAD, which meant ABI was related to SBP [28].
There are also some parameters, such as BMI, triglycerides, and LDL levels, that are strongly associated with CAVI in our study. A previous study proved that high triglycerides were strongly associated with high CAVI independent of multiple cardiometabolic risk factors. This can be explained by the statistics that show that the triglycerides were positively associated with CAVI. There was also a report showing that TG was found to be associated with a risk of higher CAVI [29]. In our study, triglycerides had a significant association with CAVI: the higher the triglyceride level, the higher the CAVI.
There is a linear association between CAVI and age [30]; as patients age, their CAVI levels tend to increase. The duration of DM is associated with CAVI; based on the review, the CAVI has a linear association with the duration of diabetes, so the CAVI level might be a suitable tool for evaluating the duration of diabetes: the longer the patients had DM, the more possible abnormal CAVI level may happen.
Alpha-blocker, which mainly acts on α-adrenergic receptors to produce vasodilation, reduces systemic vascular resistance, and achieves an antihypertensive effect, has the function of dilating blood vessels and lowering blood pressure; however, the CAVI is a parameter of vascular stiffness that does not depend on blood pressure [14], so it is a good tool to evaluate patients’ conditions.
Diuretics are mainly used in renal disease to facilitate extracellular fluid volume control, reduce the chance of developing hyperkalemia, and lower blood pressure. Furthermore, based on the results of the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Joint National Committee (JNC) 7, diuretics are recommended as preferred agents in the general population with hypertension to lower their blood pressure and reduce CVD risk [31]. Accordingly, of these chronic kidney disease patients who used diuretics, most of them had CVD risk. In our study, it was associated with TBI.
In our study, patients who used non-sulfonylureas meglitinides were associated with CAVI and TBI. When patients use sulfonylureas as medicine to control their type 2 DM, the risk of hypoglycemia needs to be considered, mainly because of the decreased clearance of insulin and oral hypoglycemic drugs and impaired renal gluconeogenesis [32]. The patients with advanced stages of CKD 3 to 5 should consider short-acting non-sulfonylureas meglitinides as their priority to avoid hypoglycemia events, this might explain why meglitinide use was associated with the TBI in CKD stages 3 to 5 and CAVI in CKD stages 1 to 3a. Furthermore, based on the previous study, CAVI was decreased significantly in pioglitazone users but remained unchanged after treatment with sulfonylureas medicine like glimepiride [33].
The strength of our study is that this is the first and only study that compares the three measures of TBI, ABI, and CAVI together among patients with DKD. In the previous studies of Japan and the United States, only two measures with TBI and ABI were compared. The limitation of this study is that the gold standard for diagnosing PAD like angiography was not conducted in our study, because of the risk of progressing to hemodialysis after the procedures, especially for the advanced stages of CKD. The other limitation was that we were not able to include the smoking history of the study population.
In conclusion, TBI has a higher yield of PAD compared to ABI in this sample of Taiwanese patients with diabetic kidney disease, especially in advanced stages of CKD. CAVI may play a role in the early stage of DKD.
Author Contributions
Conceptualization, M.-Y.L., Y.-W.S., Y.-T.H. and Y.-C.C.; methodology, Y.-W.S. and Y.-T.H.; software, Y.-T.H.; validation, Y.-C.C.; formal analysis, M.-Y.L. and Y.-T.H.; investigation, Y.-W.S.; resources, M.-Y.L.; data curation, M.-Y.L., Y.-W.S., Y.-T.H. and Y.-C.C.; writing—C.-W.C.; writing—review and editing, C.-W.C., Y.-W.S., Y.-T.H., Y.-C.C. and M.-Y.L.; visualization, C.-W.C.; supervision, M.-Y.L.; project administration, M.-Y.L.; funding acquisition, C.-W.C. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by Kaohsiung Medical University Hospital KMUH-110-0M16 and KMUH-108-8R19.
Institutional Review Board Statement
This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Kaohsiung Medical University Hospital KMUH IRB-E(I) 20210313.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study. Written informed consent was obtained from the patient(s) to publish this paper.
Data Availability Statement
The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy.
Acknowledgments
We acknowledge the technical support of Ying-Lan Kou and Chi-Chen Lee.
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
References
- Isomaa, B.; Almgren, P.; Tuomi, T.; Forsen, B.; Lahti, K.; Nissen, M.; Taskinen, M.R.; Groop, L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24, 683–689. [Google Scholar] [CrossRef] [PubMed]
- Jankowski, J.; Floege, J.; Fliser, D.; Böhm, M.; Marx, N. Cardiovascular Disease in Chronic Kidney Disease. Circulation 2021, 143, 1157–1172. [Google Scholar] [CrossRef] [PubMed]
- Fowkes, F.G.; Rudan, D.; Rudan, I.; Aboyans, V.; Denenberg, J.O.; McDermott, M.M.; Norman, P.E.; Sampson, U.K.; Williams, L.J.; Mensah, G.A.; et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013, 382, 1329–1340. [Google Scholar] [CrossRef] [PubMed]
- Selvin, E.; Erlinger, T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004, 110, 738–743. [Google Scholar] [CrossRef] [PubMed]
- Khan, T.H.; Farooqui, F.A.; Niazi, K. Critical review of the ankle brachial index. Curr. Cardiol. Rev. 2008, 4, 101–106. [Google Scholar] [CrossRef]
- Everhart, J.E.; Pettitt, D.J.; Knowler, W.C.; Rose, F.A.; Bennett, P.H. Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia 1988, 31, 16–23. [Google Scholar] [CrossRef]
- Toussaint, A.N.D.; Kerr, P.G. Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology 2007, 12, 500–509. [Google Scholar] [CrossRef]
- Young, M.J.; Adams, J.E.; Anderson, G.F.; Boulton, A.J.; Cavanagh, P.R. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 1993, 36, 615–621. [Google Scholar] [CrossRef]
- Foley, R.N.; Parfrey, P.S.; Sarnak, M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998, 32, 112–119. [Google Scholar] [CrossRef]
- Fowkes, F.G.; Housley, E.; Riemersma, R.A.; MacIntyre, C.C.; Cawood, E.H.; Prescott, R.J.; Ruckley, C.V. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the edinburgh artery study. Am. J. Epidemiol. 1992, 135, 331–340. [Google Scholar] [CrossRef]
- Tomiyama, H.; Yamashina, A.; Arai, T.; Hirose, K.; Koji, Y.; Chikamori, T.; Hori, S.; Yamamoto, Y.; Doba, N.; Hinohara, S. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—A survey of 12517 subjects. Atherosclerosis 2003, 166, 303–309. [Google Scholar] [CrossRef] [PubMed]
- Yamashina, A.; Tomiyama, H.; Takeda, K.; Tsuda, H.; Arai, T.; Hirose, K.; Koji, Y.; Hori, S.; Yamamoto, Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens. Res. 2002, 25, 359–364. [Google Scholar] [CrossRef] [PubMed]
- Yokoyama, H.; Shoji, T.; Kimoto, E.; Shinohara, K.; Tanaka, S.; Koyama, H.; Emoto, M.; Nishizawa, Y. Pulse wave velocity in lower-limb arteries among diabetic patients with peripheral arterial disease. J. Atheroscler. Thromb. 2003, 10, 253–258. [Google Scholar] [CrossRef] [PubMed]
- Shirai, K.; Hiruta, N.; Song, M.; Kurosu, T.; Suzuki, J.; Tomaru, T.; Miyashita, Y.; Saiki, A.; Takahashi, M.; Suzuki, K.; et al. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: Theory, evidence and perspectives. J. Atheroscler. Thromb. 2011, 18, 924–938. [Google Scholar] [CrossRef] [PubMed]
- Shirai, K.; Utino, J.; Otsuka, K.; Takata, M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J. Atheroscler. Thromb. 2006, 13, 101–107. [Google Scholar] [CrossRef] [PubMed]
- Vickery, S.; Stevens, P.E.; Dalton, R.N.; van Lente, F.; Lamb, E.J. Does the id-ms traceable mdrd equation work and is it suitable for use with compensated jaffe and enzymatic creatinine assays? Nephrol. Dial. Transplant. 2006, 21, 2439–2445. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med. 1999, 130, 461–470. [Google Scholar] [CrossRef]
- Georgescu, O.; Nica, C.; Crăciun, S.; Toader, C.; Ioacără, S.; Fica, S. Arterial Stiffness and Impaired Renal Function in Patients With and Without Diabetes Mellitus. Rom. J. Diabetes Nutr. Metab. Dis. 2014, 21, 89–95. [Google Scholar] [CrossRef]
- Gerhard-Herman, M.D.; Gornik, H.L.; Barrett, C.; Barshes, N.R.; Corriere, M.A.; Drachman, D.E.; Fleisher, L.A.; Fowkes, F.G.R.; Hamburg, N.M.; Kinlay, S.; et al. Guideline on the management of patients with lower extremity peripheral artery disease: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2017, 135, e726–e779. [Google Scholar]
- Bourrier, M.; Ferguson, T.W.; Embil, J.M.; Rigatto, C.; Komenda, P.; Tangri, N. Peripheral artery disease: Its adverse consequences with and without CKD. Am. J. Kidney Dis. 2020, 75, 705–712. [Google Scholar] [CrossRef]
- Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. Suppl. 2012, 2, 337–414. [Google Scholar]
- Arora, E.; Maiya, A.G.; Devasia, T.; Bhat, R.; Kamath, G. Prevalence of peripheral arterial disease among type 2 diabetes mellitus in coastal Karnataka. Diabetes Metab. Syndr. 2019, 13, 1251–1253. [Google Scholar] [CrossRef]
- Leskinen, Y.; Salenius, J.P.; Lehtimaki, T.; Huhtala, H.; Saha, H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: Requirements for diagnostics. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2002, 40, 472–479. [Google Scholar] [CrossRef]
- Suominen, V.; Uurto, I.; Saarinen, J.; Venermo, M.; Salenius, J. PAD as a risk factor for mortality among patients with elevated ABI—A clinical study. Eur. J. Vasc. Endovasc. Surg. 2010, 39, 316–322. [Google Scholar] [CrossRef]
- Liu, J.; Liu, H.; Zhao, H.; Shang, G.; Zhou, Y.; Li, L.; Wang, H. Descriptive study of relationship between cardio-ankle vascular index and biomarkers in vascular-related diseases. Clin. Exp. Hypertens. 2017, 39, 468–472. [Google Scholar] [CrossRef]
- Nam, S.H.; Kang, S.G.; Lee, Y.A.; Song, S.W.; Rho, J.S. Association of Metabolic Syndrome with the Cardio ankle vascular index in asymptomatic Korean population. J. Diabetes Res. 2015, 2015, 328585. [Google Scholar] [CrossRef]
- Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.; Smith, S.C., Jr.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation 2009, 120, 1640–1645. [Google Scholar]
- Espeland, M.A.; Regensteiner, J.G.; Jaramillo, S.A.; Gregg, E.; Knowler, W.C.; Wagenknecht, L.E.; Bahnson, J.; Haffner, S.; Hill, J.; Hiatt, W.R. Measurement characteristics of the ankle–brachial index: Results from the Action for Health in Diabetes study. Medicine 2020, 99, e18598. [Google Scholar] [CrossRef]
- Sekizuka, H.; Hoshide, S.; Kabutoya, T.; Kario, K. Determining the Relationship between Triglycerides and Arterial Stiffness in Cardiovascular Risk Patients without Low-Density Lipoprotein Cholesterol-Lowering Therapy. Int. Heart J. 2021, 62, 1320–1327. [Google Scholar] [CrossRef]
- Wohlfahrt, P.; Cífková, R.; Movsisyan, N.; Kunzová, Š.; Lešovský, J.; Homolka, M.; Soška, V.; Dobšák, P.; Lopez-Jimenez, F.; Sochor, O. Reference values of cardio-ankle vascular index in a random sample of a white population. J. Hypertens. 2017, 35, 2238–2244. [Google Scholar] [CrossRef]
- Chang, C.-C.; Chen, Y.-T.; Hsu, C.-Y.; Su, Y.-W.; Chiu, C.-C.; Leu, H.-B.; Huang, P.-H.; Chen, J.-W.; Lin, S.-J. Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients. Am. J. Med. 2017, 130, 348–355. [Google Scholar] [CrossRef]
- Ioannidis, I. Diabetes treatment in patients with renal disease: Is the landscape clear enough? World J. Diabetes 2014, 5, 651–658. [Google Scholar] [CrossRef]
- Ohira, M.; Yamaguchi, T.; Saiki, A.; Ban, N.; Kawana, H.; Nagumo, A.; Murano, T.; Shirai, K.; Tatsuno, I. Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin. Diabetes Metab. Syndr. Obes. 2014, 7, 313–319. [Google Scholar] [CrossRef]
Table 1.
(A) Distribution of subjects according to clinical characteristics and ankle-branchial index (ABI) results. (B) Distribution of subjects according to clinical characteristics and toe-branchial index (TBI) results. (C) Distribution of subjects according to clinical characteristics and cardio-ankle vascular index (CAVI) results.
Table 1.
(A) Distribution of subjects according to clinical characteristics and ankle-branchial index (ABI) results. (B) Distribution of subjects according to clinical characteristics and toe-branchial index (TBI) results. (C) Distribution of subjects according to clinical characteristics and cardio-ankle vascular index (CAVI) results.
| (A) | ||||
| ABI | p-Value | |||
| All Patients N = 368 | Abnormal (<0.9) N = 32 (8.7%) | Normal (>0.9) N = 336 (91.3%) | ||
| Normal (reference) | 82 | 3 (9.4%) | 79 (23.5%) | 0.0067 * |
| Chronic Kidney Disease | ||||
| Stage 1 | 39 | 3 (9.4%) | 36 (10.7%) | |
| Stage 2 | 60 | 4 (12.5%) | 56 (16.7%) | . |
| Stage 3a | 92 | 5 (15.6%) | 87 (25.9%) | . |
| Stage 3b | 60 | 9 (28.1%) | 51 (15.2%) | . |
| Stage 4 + 5 | 35 | 8 (25.0%) | 27 (8.0%) | . |
| Age (years) | 368 | 68.59 ± 13.14 | 67.03 ± 10.76 | 0.4411 |
| Diabetes mellitus duration (years) | 368 | 18.07 ± 9.11 | 15.60 ± 9.46 | 0.1711 |
| Sex | ||||
| Male | 190 | 13 (40.6%) | 177 (52.7%) | 0.1629 |
| Female | 178 | 19 (59.4%) | 159 (47.3%) | . |
| Urine ACR (mg/g) | ||||
| 0–29 | 159 | 10 (31.3%) | 149 (44.3%) | 0.0396 * |
| 30–299 | 137 | 10 (31.3%) | 127 (37.8%) | |
| ≥300 | 72 | 12 (37.5%) | 60 (17.9%) | |
| Total Cholesterol (mg/dL) | 290 | 151.20 ± 25.43 | 153.30 ± 37.73 | 0.7184 |
| Triglycerides (mg/dL) | 366 | 133.30 ± 80.11 | 119.20 ± 92.55 | 0.4137 |
| High-density lipoprotein (mg/dL) | 365 | 46.18 ± 16.94 | 49.07 ± 15.66 | 0.3306 |
| Low-density lipoprotein (mg/dL) | 368 | 69.07 ± 20.67 | 75.28 ± 26.67 | 0.2015 |
| Creatinine (mg/dL) | 365 | 1.79 ± 1.49 | 1.35 ± 1.38 | 0.0843 |
| Fasting glucose (mg/dL) | 360 | 143.70 ± 54.81 | 133.30 ± 39.07 | 0.3055 |
| Hemoglobin A1C (%) | 368 | 7.09 ± 1.23 | 7.43 ± 4.60 | 0.3063 |
| Body mass index (kg/m2) | 367 | 27.64 ± 5.68 | 26.92 ± 5.59 | 0.4866 |
| Systolic blood pressure (mmHg) | 367 | 137.20 ± 16.92 | 131.50 ± 15.28 | 0.0487 * |
| Diastolic blood pressure (mmHg) | 367 | 75.88 ± 10.52 | 75.14 ± 11.26 | 0.7232 |
| Hypertension | 260 | 24 (75.0%) | 236 (70.2%) | 0.5719 |
| Dyslipidemia | 306 | 27 (84.4%) | 279 (83.0%) | 0.8466 |
| Cardiovascular Disease | 88 | 14 (43.8%) | 74 (22.0%) | 0.0059 * |
| Antidiabetic agent | ||||
| Sulfonylureas | 182 | 15 (46.9%) | 167 (49.7%) | 0.7599 |
| Metformin | 257 | 16 (50.0%) | 241 (71.7%) | 0.0105 * |
| Meglitinides | 15 | 3 (9.4%) | 12 (3.6%) | 0.1126 |
| Thiazolidinediones | 123 | 8 (25.0%) | 115 (34.2%) | 0.2904 |
| Alpha-glucosidase inhibitors | 31 | 3 (9.4%) | 28 (8.3%) | 0.8394 |
| Dipeptidyl-peptidase 4 inhibitors | 124 | 7 (21.9%) | 117 (34.8%) | 0.1387 |
| Sodium-glucose Co-transporter 2 inhibitors | 152 | 12 (37.5%) | 140 (41.7%) | 0.6474 |
| Insulin | 114 | 14 (43.8%) | 100 (29.8%) | 0.1020 |
| Antihypertensives | ||||
| Angiotensin converting enzyme inhibitors | 19 | 0 (0%) | 19 (5.7%) | 0.1665 |
| Angiotensin II receptor blocker | 175 | 17 (53.1%) | 158 (47.2%) | 0.5189 |
| Beta-blocker | 93 | 9 (28.1%) | 84 (25.1%) | 0.7047 |
| Calcium Channel Blocker | 166 | 17 (53.1%) | 149 (44.5%) | 0.3477 |
| Diuretic | 40 | 3 (9.4%) | 37 (11.0%) | 0.7721 |
| Alpha-blocker | 21 | 4 (12.5%) | 17 (5.1%) | 0.0840 |
| Antihyperlipidemic agent | ||||
| Stain | 292 | 27 (84.4%) | 265 (78.9%) | 0.4622 |
| Fibrates | 40 | 3 (9.4%) | 37 (11.0%) | 0.7762 |
| Other lipid-lowering agents | 25 | 1 (3.1%) | 24 (7.1%) | 0.3881 |
| (B) | ||||
| TBI | p-Value | |||
| All Patients N = 368 | Abnormal (<0.65) N = 78 (21.2%) | Normal (>0.65) N = 290 (78.8%) | ||
| Normal (reference) | 82 | 7 (9.4%) | 75 (23.5%) | 0.0039 * |
| Chronic Kidney Disease | ||||
| Stage 1 | 39 | 6 (7.7%) | 33 (11.4%) | |
| Stage 2 | 60 | 11 (14.1%) | 49 (16.9%) | . |
| Stage 3a | 92 | 25 (32.1%) | 67 (23.1%) | . |
| Stage 3b | 60 | 16 (20.5%) | 44 (15.2%) | . |
| Stage 4 + 5 | 35 | 13 (16.7%) | 22 (7.6%) | . |
| Age (years) | 368 | 69.09 ± 11.03 | 66.64 ± 10.92 | 0.0808 |
| Diabetes mellitus duration (years) | 368 | 17.37 ± 9.27 | 15.38 ± 9.46 | 0.1057 |
| Sex | ||||
| Male | 190 | 44 (56.4%) | 146 (50.3%) | 0.3413 |
| Female | 178 | 34 (43.6%) | 144 (49.7%) | . |
| Urine ACR (mg/g) | ||||
| 0–29 | 159 | 30 (38.5%) | 129 (44.5%) | 0.5543 |
| 30–299 | 137 | 30 (38.5%) | 107 (36.9%) | |
| ≥300 | 72 | 18 (23.1%) | 54 (18.6%) | |
| Total Cholesterol (mg/dL) | 290 | 151.70 ± 35.65 | 153.50 ± 37.26 | 0.7273 |
| Triglycerides (mg/dL) | 366 | 111.90 ± 61.97 | 122.70 ± 97.99 | 0.2366 |
| High-density lipoprotein (mg/dL) | 365 | 47.60 ± 14.28 | 49.15 ± 16.16 | 0.4408 |
| Low-density lipoprotein (mg/dL) | 368 | 74.51 ± 25.91 | 74.80 ± 26.37 | 0.9310 |
| Creatinine (mg/dL) | 365 | 1.62 ± 1.71 | 1.32 ± 1.29 | 0.1540 |
| Fasting glucose (mg/dL) | 360 | 141.10 ± 55.19 | 132.30 ± 35.80 | 0.1927 |
| Hemoglobin A1C (%) | 368 | 7.24 ± 1.38 | 7.44 ± 4.92 | 0.5378 |
| Body mass index (kg/m2) | 367 | 26.80 ± 5.80 | 27.03 ± 5.55 | 0.7496 |
| Systolic blood pressure (mmHg) | 367 | 132.10 ± 18.38 | 132.01 ± 14.64 | 0.9871 |
| Diastolic blood pressure (mmHg) | 367 | 74.56 ± 12.19 | 75.38 ± 10.92 | 0.5697 |
| Hypertension | 260 | 58 (74.4%) | 202 (69.7%) | 0.4180 |
| Dyslipidemia | 306 | 68 (87.2%) | 238 (82.1%) | 0.2844 |
| Cardiovascular Disease | 88 | 31 (39.7%) | 57 (19.7%) | 0.0002 * |
| Antidiabetic agent | ||||
| Sulfonylureas | 182 | 37 (47.4%) | 145 (50.0%) | 0.6876 |
| Metformin | 257 | 48 (61.5%) | 209 (72.1%) | 0.0720 |
| Meglitinides | 15 | 8 (10.3%) | 7 (2.4%) | 0.0019 * |
| Thiazolidinediones | 123 | 31 (39.7%) | 92 (31.7%) | 0.1826 |
| Alpha-glucosidase inhibitors | 31 | 10 (12.8%) | 21 (7.2%) | 0.1153 |
| Dipeptidyl-peptidase 4 inhibitors | 124 | 30 (38.5%) | 94 (32.4%) | 0.3158 |
| Sodium-glucose Co-transporter 2 inhibitors | 152 | 28 (35.9%) | 124 (42.8%) | 0.2746 |
| Insulin | 114 | 25 (32.1%) | 89 (30.7%) | 0.8174 |
| Antihypertensives | ||||
| Angiotensin converting enzyme inhibitors | 19 | 3 (3.8%) | 16 (5.5%) | 0.5499 |
| Angiotensin II receptor blocker | 175 | 41 (52.6%) | 134 (46.4%) | 0.3308 |
| Beta-blocker | 93 | 20 (25.6%) | 73 (25.3%) | 0.9452 |
| Calcium Channel Blocker | 166 | 35 (44.9%) | 131 (45.3%) | 0.9426 |
| Diuretic | 40 | 18 (23.1%) | 22 (7.6%) | 0.0001 * |
| Alpha-blocker | 21 | 4 (5.1%) | 17 (5.9%) | 0.7991 |
| Antihyperlipidemic agent | ||||
| Stain | 292 | 66 (84.6%) | 226 (77.9%) | 0.1955 |
| Fibrates | 40 | 8 (10.3%) | 32 (11.0%) | 0.8446 |
| Other lipid-lowering agents | 25 | 9 (11.5%) | 16 (5.5%) | 0.0607 |
| (C) | ||||
| CAVI | p-Value | |||
| All Patients N = 368 | Abnormal (>9) N = 168 (45.7%) | Normal (<9) N = 200 (54.3%) | ||
| Normal (reference) | 82 | 41 (50.0%) | 41 (50.0%) | 0.0820 |
| Chronic Kidney Disease | ||||
| Stage 1 | 39 | 11 (6.5%) | 28 (14.0%) | |
| Stage 2 | 60 | 22 (13.1%) | 38 (19.0%) | . |
| Stage 3a | 92 | 44 (26.2%) | 48 (24.0%) | . |
| Stage 3b | 60 | 33 (19.6%) | 27 (13.5%) | . |
| Stage 4 + 5 | 35 | 17 (10.1%) | 18 (9.0%) | . |
| Age (years) | 368 | 71.91 ± 8.64 | 63.18 ± 11.16 | <0.0001 * |
| Diabetes mellitus duration (years) | 368 | 17.77 ± 9.31 | 14.13 ± 9.25 | 0.0003 * |
| Sex | ||||
| Male | 190 | 91 (54.2%) | 99 (49.5%) | 0.3722 |
| Female | 178 | 77 (45.8%) | 101 (50.5%) | . |
| Urine ACR (mg/g) | ||||
| 0–29 | 159 | 78 (46.4%) | 81 (40.5%) | 0.5200 |
| 30–299 | 137 | 59 (35.1%) | 78 (39.0%) | |
| ≥300 | 72 | 31 (18.5%) | 41 (20.5%) | |
| Total Cholesterol (mg/dL) | 290 | 151.90 ± 36.02 | 154.20 ± 37.66 | 0.5998 |
| Triglycerides (mg/dL) | 366 | 121.20 ± 89.95 | 119.70 ± 93.10 | 0.8740 |
| High-density lipoprotein (mg/dL) | 365 | 47.53 ± 14.25 | 49.92 ± 16.92 | 0.1422 |
| Low-density lipoprotein (mg/dL) | 368 | 73.64 ± 24.57 | 75.65 ± 27.59 | 0.4656 |
| Creatinine (mg/dL) | 365 | 1.43 ± 1.51 | 1.35 ± 1.29 | 0.5667 |
| Fasting glucose (mg/dL) | 360 | 135.90 ± 41.08 | 132.70 ± 40.37 | 0.4479 |
| Hemoglobin A1C (%) | 368 | 7.55 ± 4.98 | 7.27 ± 3.87 | 0.5531 |
| Body mass index (kg/m2) | 367 | 25.69 ± 5.20 | 28.06 ± 5.70 | <0.0001 * |
| Systolic blood pressure (mmHg) | 367 | 132.70 ± 15.17 | 131.50 ± 5.76 | 0.4610 |
| Diastolic blood pressure (mmHg) | 367 | 75.17 ± 11.67 | 75.23 ± 10.80 | 0.9618 |
| Hypertension | 260 | 120 (71.4%) | 140 (70.0%) | 0.7643 |
| Dyslipidemia | 306 | 136 (81.0%) | 170 (85.0%) | 0.3015 |
| Cardiovascular Disease | 88 | 34 (20.2%) | 54 (27.0%) | 0.1298 |
| Antidiabetic agent | ||||
| Sulfonylureas | 182 | 82 (48.8%) | 100 (50.0%) | 0.8200 |
| Metformin | 257 | 110 (65.5%) | 147 (73.5%) | 0.0948 |
| Meglitinides | 15 | 12 (7.1%) | 3 (1.5%) | 0.0064 * |
| Thiazolidinediones | 123 | 56 (33.3%) | 67 (33.5%) | 0.9731 |
| Alpha-glucosidase inhibitors | 31 | 20 (11.9%) | 11 (5.5%) | 0.0276 * |
| Dipeptidyl-peptidase4 inhibitors | 124 | 62 (36.9%) | 62 (31.0%) | 0.2326 |
| Sodium-glucose Co-transporter 2 inhibitors | 152 | 69 (41.1%) | 83 (41.5%) | 0.9337 |
| Insulin | 114 | 59 (35.1%) | 55 (27.5%) | 0.1154 |
| Antihypertensives | ||||
| Angiotensin converting enzyme inhibitors | 19 | 7 (4.2%) | 12 (6.0%) | 0.4221 |
| Angiotensin II receptor blocker | 175 | 81 (48.2%) | 94 (47.2%) | 0.8517 |
| Beta-blocker | 93 | 39 (23.2%) | 54 (27.1%) | 0.3895 |
| Calcium Channel Blocker | 166 | 78 (46.4%) | 88 (44.2%) | 0.6721 |
| Diuretic | 40 | 18 (10.7%) | 22 (11.1%) | 0.9168 |
| Alpha-blocker | 21 | 5 (3.0%) | 16 (8.0%) | 0.0374 * |
| Antihyperlipidemic agent | ||||
| Stain | 292 | 130 (77.4%) | 162 (81.0%) | 0.3930 |
| Fibrates | 40 | 18 (10.7%) | 22 (11.0%) | 0.9301 |
| Other lipid-lowering agents | 25 | 12 (7.1%) | 13 (6.5%) | 0.8071 |
* p-value < 0.05.
Table 2.
Multivariate analysis of ABI, TBI, and CAVI with different parameters.
| ABI | TBI | CAVI | |||||||
|---|---|---|---|---|---|---|---|---|---|
| AOR | 95% CI | p-Value | AOR | 95% CI | p-Value | AOR | 95% CI | p-Value | |
| Chronic kidney disease | |||||||||
| Stage 1 | 16.00 | 0.58–443.12 | 0.1018 | 6.17 | 0.89–42.61 | 0.0651 | 0.16 | 0.03–0.77. | 0.0223 * |
| Stage 2 | 4.93 | 0.22–112.26 | 0.3173 | 5.49 | 0.98–30.87 | 0.0535 | 0.18 | 0.04–0.74. | 0.0180 * |
| Stage 3a | 1.30 | 0.10–17.22 | 0.8400 | 6.50 | 1.63–25.97 | 0.0080 * | 0.31 | 0.10–0.93. | 0.0375 * |
| Stage 3b | 6.54 | 0.47–91.56 | 0.1631 | 7.47 | 1.52–36.81 | 0.0135 * | 0.38 | 0.10–1.44. | 0.1552 |
| Stage 4 + 5 | 11.34 | 0.22–589.91 | 0.2285 | 20.13 | 1.96–206.92 | 0.0116 * | 0.35 | 0.04–3.03. | 0.3388 |
| Age | 1.05 | 0.98–1.13 | 0.1747 | 1.00 | 0.96–1.05 | 0.8878 | 1.11 | 1.07–1.16. | <0.0001 * |
| Diabetes mellitus | 0.98 | 0.91–1.06 | 0.6270 | 1.00 | 0.96–1.04 | 0.9383 | 1.05 | 1.01–1.09. | 0.0282 * |
| duration (years) | |||||||||
| Sex | 1.11 | 0.28–4.37 | 0.8778 | 1.62 | 0.75–3.53 | 0.2218 | 1.11 | 0.57–2.16. | 0.7560 |
| Urine ACR (mg/g) 30–299 | 0.15 | 0.02–1.47 | 0.1022 | 0.78 | 0.24–2.54 | 0.6820 | 1.45 | 0.49–4.34. | 0.5042 |
| ≥300 | 0.18 | 0.01–2.71 | 0.2157 | 0.57 | 0.14–2.36 | 0.4410 | 2.20 | 0.54–8.99. | 0.2713 |
| Total Cholesterol (mg/dL) | 0.99 | 0.91–1.07 | 0.8015 | 1.00 | 0.94–1.06 | 0.9974 | 0.95 | 0.91–1.00. | 0.0556 |
| Triglycerides (mg/dL) | 1.01 | 0.99–1.03 | 0.5685 | 1.00 | 0.98–1.01 | 0.4962 | 1.01 | 1.00–1.02. | 0.0120 * |
| High-density lipoprotein (mg/dL) | 1.01 | 0.91–1.13 | 0.7916 | 0.99 | 0.92–1.06 | 0.7823 | 1.04 | 0.98–1.10. | 0.2218 |
| Low-density lipoprotein (mg/dL) | 1.01 | 0.92–1.11 | 0.7942 | 1.01 | 0.94–1.07 | 0.8820 | 1.06 | 1.00–1.12. | 0.0388 * |
| Creatinine (mg/dL) | 0.81 | 0.36–1.78 | 0.5926 | 0.96 | 0.73–1.28 | 0.7893 | 0.80 | 0.60–1.07. | 0.1350 |
| Fasting glucose (mg/dL) | 1.01 | 0.99–1.04 | 0.2031 | 1.01 | 1.00–1.02 | 0.1551 | 1.00 | 0.99–1.01. | 0.5792 |
| Hemoglobin A1C (%) | 0.65 | 0.29–1.43 | 0.2842 | 0.96 | 0.81–1.14 | 0.6725 | 1.06 | 0.97–1.16. | 0.1886 |
| Body mass index (kg/m2) | 1.01 | 0.88–1.17 | 0.8839 | 0.96 | 0.90–1.03 | 0.2220 | 0.92 | 0.85–0.99. | 0.0223 * |
| Systolic blood pressure (mmHg) | 1.12 | 1.03–1.21 | 0.0090 | 1.01 | 0.97–1.06 | 0.5000 | 1.00 | 0.96–1.03. | 0.7998 |
| Diastolic blood pressure (mmHg) | 0.91 | 0.82–1.01 | 0.0612 | 1.00 | 0.95–1.05 | 0.9161 | 1.01 | 0.96–1.06. | 0.6553 |
| Hypertension | 0.52 | 0.05–5.87 | 0.5960 | 1.26 | 0.34–4.61 | 0.7274 | 0.93 | 0.29–2.92. | 0.8971 |
| Dyslipidemia | - | - | - | 0.82 | 0.06–11.86 | 0.8843 | 0.52 | 0.06–4.31. | 0.5415 |
| Cardiovascular Disease | 7.19 | 1.75–29.59 | 0.0063 * | 4.00 | 1.76–9.11 | 0.0010 * | 0.50 | 0.23–1.06. | 0.0711 |
| Antidiabetic agent | |||||||||
| Sulfonylureas | 1.53 | 0.31–7.56 | 0.6023 | 0.88 | 0.39–2.01 | 0.7590 | 1.01 | 0.49–2.08. | 0.9884 |
| Metformin | 0.75 | 0.12–4.84 | 0.7631 | 2.53 | 0.84–7.64 | 0.0996 | 0.93 | 0.36–2.37. | 0.8702 |
| Meglitinides | 7.84 | 0.23–265.48 | 0.2518 | 6.13 | 1.05–35.87 | 0.0444 * | 47.27 | 2.63–848.93. | 0.0089 * |
| Thiazolidinediones | 0.92 | 0.18–4.66 | 0.9200 | 2.14 | 0.87–5.26 | 0.0984 | 0.90 | 0.40–2.01. | 0.7971 |
| Alpha-glucosidase inhibitors | 0.45 | 0.04–4.75 | 0.5086 | 1.14 | 0.32–4.09 | 0.8447 | 2.55 | 0.77–8.45. | 0.1255 |
| Dipeptidyl-peptidase 4 inhibitors | 0.10 | 0.01–0.67 | 0.0177* | 0.41 | 0.15–1.17 | 0.0974 | 0.93 | 0.37–2.33. | 0.8816 |
| Sodium-glucose Co-transporter 2 inhibitors | 0.89 | 0.17–4.67 | 0.8924 | 0.55 | 0.20–1.47 | 0.2309 | 1.71 | 0.70–4.18. | 0.2361 |
| Insulin | 1.31 | 0.22–7.95 | 0.7713 | 0.51 | 0.20–1.33 | 0.1699 | 1.01 | 0.46–2.22. | 0.9812 |
| Antihypertensives | |||||||||
| Angiotensin converting enzyme inhibitors | 1.51 | 0.41–11.15 | 0.7230 | 1.76 | 0.29–10.61 | 0.5367 | 0.55 | 0.11–2.78. | 0.4661 |
| Angiotensin II receptor blocker | 1.49 | 0.22–10.04 | 0.6830 | 1.35 | 0.46–3.93 | 0.5809 | 0.69 | 0.26–1.80. | 0.4442 |
| Beta-blocker | 1.19 | 0.21–6.66 | 0.8469 | 1.09 | 0.45–2.67 | 0.8438 | 1.16 | 0.52–2.60. | 0.7202 |
| Calcium Channel Blocker | 0.64 | 0.12–3.61 | 0.6173 | 0.45 | 0.19–1.06 | 0.0662 | 1.64 | 0.73–3.69. | 0.2283 |
| Diuretics | 0.60 | 0.05–7.65 | 0.6958 | 4.19 | 1.36–12.90 | 0.0125 * | 1.39 | 0.46–4.16. | 0.5615 |
| Alpha-blocker | 6.61 | 0.66–65.85 | 0.1072 | 0.55 | 0.12–2.60 | 0.4486 | 0.13 | 0.03–0.60. | 0.0088 * |
| Antihyperlipidemic agent | 0.7230 | ||||||||
| Stain | 0.61 | 0.10–8.41 | 0.7585 | 1.65 | 0.15–18.70 | 0.6863 | 1.42 | 0.21–9.72. | |
| Fibrates | 0.56 | 0.04–7.46 | 0.6586 | 1.23 | 0.34–4.50 | 0.7528 | 2.90 | 0.80–10.55. | 0.1052 |
| Other lipid-lowering agent | 0.81 | 0.15–9.81 | 0.8791 | 1.85 | 0.44–7.75 | 0.4027 | 0.56 | 0.16–1.97. | 0.3655 |
* p-value < 0.05; adjusted odds ratio, AOR.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Chang, C.-W.; Sung, Y.-W.; Huang, Y.-T.; Chung, Y.-C.; Lee, M.-Y. Better Detection of Peripheral Arterial Disease with Toe-Brachial Index Compared to Ankle-Brachial Index among Taiwanese Patients with Diabetic Kidney Disease. J. Clin. Med. 2023, 12, 7393. https://doi.org/10.3390/jcm12237393
AMA Style
Chang C-W, Sung Y-W, Huang Y-T, Chung Y-C, Lee M-Y. Better Detection of Peripheral Arterial Disease with Toe-Brachial Index Compared to Ankle-Brachial Index among Taiwanese Patients with Diabetic Kidney Disease. Journal of Clinical Medicine. 2023; 12(23):7393. https://doi.org/10.3390/jcm12237393
Chicago/Turabian StyleChang, Chia-Wei, Ya-Wen Sung, Yu-Ting Huang, Yong-Chuan Chung, and Mei-Yueh Lee. 2023. "Better Detection of Peripheral Arterial Disease with Toe-Brachial Index Compared to Ankle-Brachial Index among Taiwanese Patients with Diabetic Kidney Disease" Journal of Clinical Medicine 12, no. 23: 7393. https://doi.org/10.3390/jcm12237393
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
